THE BEHAVIORAL-EFFECTS OF HEPTYL PHYSOSTIGMINE, A NEW CHOLINESTERASE INHIBITOR, IN TESTS OF LONG-TERM AND WORKING MEMORY IN RODENTS

被引:78
作者
DAWSON, GR [1 ]
BENTLEY, G [1 ]
DRAPER, F [1 ]
RYCROFT, W [1 ]
IVERSEN, SD [1 ]
PAGELLA, PG [1 ]
机构
[1] MEDIOLANUM FARMACEUT,RES LABS,MILAN,ITALY
关键词
HEPTYL PHYSOSTIGMINE; DEMENTIA; CHOLINESTERASE INHIBITORS; COGNITION; RATS; MICE;
D O I
10.1016/0091-3057(91)90045-4
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
We assessed the effects of heptyl physostigmine, a new cholinesterase inhibitor, in a mouse tail-flick (TF) test, a mouse and rat passive avoidance test, a rat conditioned suppression-of-drinking (CSD) test, a rat Random Interval (RI) response rate test and a rat delayed matching-to-position (DMTP) test. In the TF test, a dose of 8.0 mg/kg of heptyl induced a significant antinociceptive effect that was in excess of 75% of the maximum possible effect 300 minutes after administration. In the mouse passive avoidance test, a dose of 3.0 mg/kg of heptyl fully reversed, and a dose of 1.0 mg/kg partially reversed, a scopolamine-induced (0.2 mg/kg) deficit. In the rat passive avoidance test, a dose of 8.0 mg/kg fully reversed a scopolamine-induced (0.2 mg/kg) deficit, while a dose of 4.0 mg/kg of heptyl was without effect. In the same experiment, a dose of 0.6 mg/kg of physostigmine partially reversed the scopolamine-induced deficit. In the CSD test, a dose of 8.0 mg/kg of heptyl fully reversed, and doses of 1.0 and 4.0 mg/kg of heptyl partially reversed, the deficit induced by scopolamine (0.4 mg/kg). In the RI response rate test, doses of 8.0 mg/kg and 0.6 mg/kg of physostigmine fully suppressed lever pressing for food rewards. Doses of 4.0 mg/kg of heptyl and below had no effect on lever-pressing rates. In the working memory test (DMTP), 4.0 mg/kg heptyl partially reversed the scopolamine-induced deficit (0.2 mg/kg) in the number of correct choices made, but did not affect the scopolamine-induced deficit in the number of trials completed. These results suggest that heptyl is a long-lasting cholinesterase inhibitor that produces reversals of scopolamine-induced deficits in the rodent at doses that do not induce behavioral toxicity. It would appear that heptyl is a cholinesterase inhibitor that will permit a thorough assessment of the cholinergic hypothesis of dementia of the Alzheimer's type.
引用
收藏
页码:865 / 871
页数:7
相关论文
共 14 条
  • [1] NEUROTRANSMITTER-RELATED ENZYMES AND INDEXES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
    BOWEN, DM
    SMITH, CB
    WHITE, P
    DAVISON, AN
    [J]. BRAIN, 1976, 99 (SEP) : 459 - 496
  • [2] A LONG-LASTING CHOLINESTERASE INHIBITOR AFFECTING NEURAL AND BEHAVIORAL PROCESSES
    BRUFANI, M
    CASTELLANO, C
    MARTA, M
    OLIVERIO, A
    PAGELLA, PG
    PAVONE, F
    POMPONI, M
    RUGARLI, PL
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1987, 26 (03) : 625 - 629
  • [3] CHIANG TS, 1971, ARCH INT PHARMACOD T, V189, P295
  • [4] D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74
  • [5] DAVIDSON M, 1986, PSYCHOPHARMACOL BULL, V22, P101
  • [6] DAVIS KL, 1983, NEW ENGL J MED, V308, P721
  • [7] DAWSON GR, 1990, Q J EXP PSYCHOL-B, V42, P225
  • [8] THE EFFECT OF HEPTYL-PHYSOSTIGMINE, A NEW CHOLINESTERASE INHIBITOR, ON THE CENTRAL CHOLINERGIC SYSTEM OF THE RAT
    DESARNO, P
    POMPONI, M
    GIACOBINI, E
    TANG, XC
    WILLIAMS, E
    [J]. NEUROCHEMICAL RESEARCH, 1989, 14 (10) : 971 - 977
  • [9] GELARDINI C, 1990, BRIT J PHARMACOL, V101, P49
  • [10] HARRIS LS, 1964, J PHARMACOL EXP THER, V143, P141